Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells

Immunology and Cell Biology

Volumn 92, Issue 7, 2014, Pages 591-604

  Ghamlouch, Hussein ^a   Ouled Haddou, Hakim ^a   Guyart, Aude ^a   Regnier, Aline ^a,b   Trudel, Stéphanie ^a,b   Claisse, Jean François ^b   Fuentes, Vincent ^a   Royer, Bruno ^a,b   Marolleau, Jean Pierre ^a,b   Gubler, Brigitte ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD40 LIGAND; IMMUNOGLOBULIN M; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BCL 6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BACH2; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; CYTOKINE; MEMBRANE ANTIGEN;

ADULT; AGED; ANTIBODY SECRETING CELL; ARTICLE; B CELL CULTURE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CELL FATE; CELL STIMULATION; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOPHENOTYPING; LYMPH NODE; LYMPHOCYTE STRUCTURE; MALE; PLASMA CELL; PREPLASMABLAST; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; VERY ELDERLY; ANTIBODY PRODUCTION; BIOSYNTHESIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE;

AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; ANTIGENS, SURFACE; B-LYMPHOCYTES; CD40 LIGAND; CELL DIFFERENTIATION; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PHENOTYPE; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION, GENETIC;

EID: 84906060416     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.37     Document Type: Article

References (79)

1. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23: 367-386. (Pubitemid 40563174)
2. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems and decision making for antibody production. Nat Immunol 2010; 11: 681-688.
3. Schmidlin H, Diehl SA, Blom B. New insights into the regulation of human B-cell differentiation. Trends Immunol 2009; 30: 277-285.
4. Nera KP, Lassila O. Pax5-a critical inhibitor of plasma cell fate. Scand J Immunol 2006; 64: 190-199. (Pubitemid 44215107)
5. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004; 21: 81-93. (Pubitemid 38925269)
6. Turner CA Jr., Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994; 77: 297-306. (Pubitemid 24138626)
7. Neron S, Nadeau PJ, Darveau A, Leblanc JF. Tuning of CD40-CD154 interactions in human B-lymphocyte activation: A broad array of in vitro models for a complex in vivo situation. Arch Immunol Ther Exp (Warsz) 2011; 59: 25-40.
8. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V et al. Generation of polyclonal plasmablasts from peripheral blood B cells: A normal counterpart of malignant plasmablasts. Blood 2002; 100: 1113-1122. (Pubitemid 34864260)
9. Avery DT, Ellyard JI, Mackay F, Corcoran LM, Hodgkin PD, Tangye SG. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol 2005; 174: 4034-4042. (Pubitemid 40395979)
10. Dubois B, Massacrier C, Vanbervliet B, Fayette J, Briere F, Banchereau J et al. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol 1998; 161: 2223-2231. (Pubitemid 28397033)
11. Le Gallou S, Caron G, Delaloy C, Rossille D, Tarte K, Fest T. IL-2 requirement for human plasma cell generation: Coupling differentiation and proliferation by enhancing MAPK-ERK signaling. J Immunol 2012; 189: 161-173.
12. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001; 97: 1817-1822. (Pubitemid 32217251)
13. Hasbold J, Corcoran LM, Tarlinton DM, Tangye SG, Hodgkin PD. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat Immunol 2004; 5: 55-63. (Pubitemid 38081469)
14. van Kooten C, Rensink I, Aarden L, van Oers R. Differentiation of purified malignant B cells induced by PMA or by activated normal T cells. Leukemia 1993; 7: 1576-1584. (Pubitemid 23319135)
15. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
16. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: The role of antigen stimulation. J Intern Med 2008; 264: 549-562.
17. Ghamlouch H, Ouled-Haddou H, Damaj G, Royer B, Gubler B, Marolleau JP. A Combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro. PLoS ONE 2013; 8: E60370.
18. Damle RN, Calissano C, Chiorazzi N. Chronic lymphocytic leukaemia: A disease of activated monoclonal B cells. Best Pract Res Clin Haematol 2010; 23: 33-45.
19. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
20. Fu SM, Winchester RJ, Feizi T, Walzer PD, Kunkel HG. Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc Natl Acad Sci USA 1974; 71: 4487-4490.
21. Rubartelli A, Sitia R, Zicca A, Grossi CE, Ferrarini M. Differentiation of chronic lymphocytic leukemia cells: Correlation between the synthesis and secretion of immunoglobulins and the ultrastructure of the malignant cells. Blood 1983; 62: 495-504. (Pubitemid 13036104)
22. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
23. Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chainmutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010; 29: 5071-5082.
24. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80: 3173-3181. (Pubitemid 23004522)
25. Crawford DH, Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 1993; 80: 40-44. (Pubitemid 23284185)
26. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118-2128.
27. Van den Hove LE, Van Gool SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997; 11: 572-580. (Pubitemid 27173945)
28. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999; 93: 1992-2002. (Pubitemid 29128502)
29. Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013; 122: 3010-3019.
30. Gold MR. To make antibodies or not: Signaling by the B-cell antigen receptor. Trends Pharmacol Sci 2002; 23: 316-324. (Pubitemid 34765628)
31. Kazi JU, Kabir NN, Ronnstrand L. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med Oncol 2013; 30: 757.
32. Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, Scarfo L, Ranghetti P et al. Targeting B-cell anergy in chronic lymphocytic leukemia. Blood 2013; 121: 3879-3888.
33. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996; 88: 1365-1374. (Pubitemid 26276812)
34. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-665.
35. Mond JJ, Feuerstein N, June CH, Balapure AK, Glazer RI, Witherspoon K et al. Bimodal effect of phorbol ester on B-cell activation: Implication for the role of protein kinase C. J Biol Chem 1991; 266: 4458-4463. (Pubitemid 21909378)
36. Tangye SG, Weston KM, Raison RL. Phorbol ester activates CD5\+ leukaemic B cells via a T cell-independent mechanism. Immunol Cell Biol 1995; 73: 44-51.
37. van Kooten C, Rensink I, Aarden L, van Oers R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993; 7: 618-624. (Pubitemid 23139867)
38. Manocha S, Matrai Z, Osthoff M, Carter A, Pettitt AR. Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 797-800. (Pubitemid 36410984)
39. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001; 167: 3610-3618. (Pubitemid 32916053)
40. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: Cautionary notes and additional considerations and possibilities. Blood 2011; 117: 1781-1791.
41. Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006; 7: 773-782. (Pubitemid 43905877)
42. Dong HY, Browne P, Liu Z, Gangi M. PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation. Histopathology 2008; 53: 278-287.
43. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol 2011; 187: 3931-3941.
44. Vuillier F, Dumas G, Magnac C, Prevost MC, Lalanne AI, Oppezzo P et al. Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. Blood 2005; 105: 2933-2940. (Pubitemid 40446288)
45. Minuzzo S, Indraccolo S, Tosello V, Piovan E, Cabrelle A, Trentin L et al. CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients. Leukemia 2005; 19: 1099-1101. (Pubitemid 40862030)
46. Lanemo Myhrinder A, Hellqvist E, Sidorova E, Soderberg A, Baxendale H, Dahle C et al. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111: 3838-3848.
47. Zwick C, Fadle N, Regitz E, Kemele M, Stilgenbauer S, Buhler A et al. Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. Blood 2013; 121: 4708-4717.
48. Ma Y, Hendershot LM. The unfolding tale of the unfolded protein response. Cell 2001; 107: 827-830. (Pubitemid 34084974)
49. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002; 110: 1389-1398. (Pubitemid 35396907)
50. Iwakoshi NN, Lee AH, Glimcher LH. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev. 2003; 194: 29-38. (Pubitemid 36886426)
51. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107: 881-891. (Pubitemid 34084979)
52. Hebert DN, Simons JF, Peterson JR, Helenius A. Calnexin, calreticulin, and Bip/Kar2p in protein folding. Cold Spring Harb Symp Quant Biol. 1995; 60: 405-415. (Pubitemid 26202051)
53. Ochiai K, Katoh Y, Ikura T, Hoshikawa Y, Noda T, Karasuyama H et al. Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J Biol Chem. 2006; 281: 38226-38234. (Pubitemid 46041946)
54. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009; 114: 5173-5181.
55. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173: 1158-1165. (Pubitemid 38924291)
56. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006; 25: 225-236. (Pubitemid 44224149)
57. De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001; 98: 771-780.
58. Dirks W, Rome D, Ringel F, Jager K, MacLeod RA, Drexler HG. Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk Res 1999; 23: 643-651. (Pubitemid 29243869)
59. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000; 4: 22-47. (Pubitemid 34947477)
60. Inamdar KV, Bueso-Ramos CE. Pathology of chronic lymphocytic leukemia: An update. Ann Diagn Pathol 2007; 11: 363-389. (Pubitemid 47380441)
61. Medina F, Segundo C, Jimenez-Gomez G, Gonzalez-Garcia I, Campos-Caro A, Brieva JA. Higher maturity and connective tissue association distinguish resident from recently generated human tonsil plasma cells. J Leukoc Biol 2007; 82: 1430-1436. (Pubitemid 350276954)
62. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002; 99: 2154-2161. (Pubitemid 34525501)
63. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: Comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541-549.
64. Feyler S, O'Connor SJ, Rawstron AC, Subash C, Ross FM, Pratt G et al. IgM myeloma: A rare entity characterized by a CD20-CD56-CD117-immunophenotype and the t(11;14). Br J Haematol 2008; 140: 547-551. (Pubitemid 351230082)
65. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135-1144. (Pubitemid 44232007)
66. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102: 2146-2155. (Pubitemid 37122392)
67. Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005; 19: 2264-2272. (Pubitemid 41741623)
68. Pearce L, Morgan L, Lin TT, Hewamana S, Matthews RJ, Deaglio S et al. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 2010; 95: 514-517.
69. Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001; 116: 437-443. (Pubitemid 32851978)
70. Arce S, Luger E, Muehlinghaus G, Cassese G, Hauser A, Horst A et al. CD38 low IgGsecreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol 2004; 75: 1022-1028. (Pubitemid 38720643)
71. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R et al. CD27 is heterogeneously expressed in multiple myeloma: Low CD27 expression in patients with high-risk disease. Br J Haematol 2003; 121: 36-43. (Pubitemid 36461265)
72. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell phenotypic profiling. Front Immunol 2012; 3: 302.
73. Henn AD, Laski M, Yang H, Welle S, Qiu X, Miao H et al. Functionally distinct subpopulations of CpG-activated memory B Cells. Sci Rep 2012; 2: 345.
74. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P et al. The phenotype of normal, reactive and malignant plasma cells: Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-1240. (Pubitemid 44408434)
75. Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94: 701-712. (Pubitemid 29323884)
76. Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A. Phenotypic and functional characterization of human CD25\+ B cells. Immunology 2006; 117: 548-557.
77. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 2006; 37: 152-159. (Pubitemid 43099834)
78. Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009; 69: 3121-3130.
79. Kindler V, Zubler RH. Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. J Immunol 1997; 159: 2085-2090. (Pubitemid 127680995)